* 泰国富豪谢氏家族旗下制药公司--中国生物制药1177.HK周三早盘涨幅扩大至4.9%。
* 该公司此前公告称，集团开发的盐酸安罗替尼胶囊联合化疗方案，已获得中国国家药品监督管理局批准，用于局部晚期或转移性软组织肉瘤患者的一线治疗。
* 中国生物制药今年迄今劲涨69.7%，同期恒生指数.HSI大幅上扬20.5%。
* 恒生香港上市生物科技指数.HSHKBIO盘中一度升3.1%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 张喜良)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.